BridgeBio Pharma Reports Q3 2026 Financial Results with $353.2M in Revenue and Updates on Key Catalysts

BridgeBio Pharma, Inc. (BBIO) Q3 2026 Financial & Operational Highlights

Key Financial Results

• Total Revenues: Reached $353.2 million for Q3 2026, compared to $120.7 million in Q3 2025 (a 193% year-over-year increase).
  • Net Product Revenue: $253.3 million ($253.2 million from U.S. Attruby, up ~$31 million sequentially and ~$145 million year-over-year).
  • License & Services Revenue: $79.3 million, driven by a one-time $75.0 million sales milestone under the Bayer License Agreement.
  • Royalty Revenue: $20.5 million, primarily from net product sales of BEYONTTRA in the EU and Japan.
• Loss from Operations: Narrowed to $11.6 million for the quarter.
• Balance Sheet Strength: Cash, cash equivalents, and marketable securities totaled $1.5 billion as of September 30, 2026 (up from $587.5 million as of December 31, 2025).

Pipeline & Upcoming Regulatory Catalysts

• BBP-418 (LGMD2I/R9): PDUFA action date set for November 27, 2026 with Priority Review; EMA MAA planned for 1H 2028.
• Oral Infigratinib (Achondroplasia): PDUFA action date set for February 4, 2027 with Priority Review; MAA under review with the EMA.
• Encaleret (ADH1): PDUFA action date set for May 8, 2027 with Priority Review; MAA under review with the EMA. First participant dosed in Phase 3 RECLAIM-HP for chronic hypoparathyroidism.
• BBP-717 (ATTR-CM Depleter): Development candidate nominated; IND submission anticipated in 2027.